Download PDF
Thromb Haemost 1989; 62(02): 694-698
DOI: 10.1055/s-0038-1646885
Original Article
Schattauer GmbH Stuttgart

Effect of Heparin and/or Antithrombin III on the Generation of Endotoxin-Induced Plasminogen Activator Inhibitor

C Gómez
The Haematology Service, University Clinic, University of Navarra, Pamplona, Spain
,
J A Páramo
The Haematology Service, University Clinic, University of Navarra, Pamplona, Spain
,
M Colucci
*   The Institute of General Pathology, University of Bari, Bari, Italy
,
E Rocha
The Haematology Service, University Clinic, University of Navarra, Pamplona, Spain
› Author Affiliations
Further Information

Publication History

Received 09 January 1989

Accepted after revision 06 April 1989

Publication Date:
30 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

It has been experimentally shown that endotoxin induces a significant increase in the blood levels of a plasminogen activator inhibitor (PAI). We evaluated the effect of different doses of heparin (5 to 20IU kg−1 h−1), antithrombin III (10 to 40 U kg−1 h−1 and 240 U/kg as bolus) and of a combination of the two on: 1) the elevation of PAI activity, 2) fibrin deposition in kidneys and 3) mortality in rabbits infused with E. coli lipopoly-saccharide. Our results show that heparin plus AT III is able to significantly reduce the generation of endotoxin-induced PAI activity in rabbits' circulation. Low dose of heparin and a bolus injection of AT III both cause a decrease in the generation of PAI at 2 but not at 6 hours of endotoxin infusion. Moreover, fibrin deposits in kidneys of animals receiving heparin plus AT III or a bolus injection of AT III were significantly reduced as compared to control rabbits. The association between low levels of PAI and decreased fibrin deposits is strengthened by the significant correlation (p < 0.05) found between these two parameters. Finally, the plasma levels of PAI activity at 2 and 6 hours of endotoxin infusion in surviving animals were lower than those observed in animals that died within 2 hours after the end of treatment. We conclude that heparin plus AT III partially prevents the endotoxin-induced generation of PAI activity which seems to correlate with the reduced presence of fibrin deposits in kidneys and with a reduced mortality.

Keywords

Disseminated intravascular coagulation - Endotoxin - Heparin - Antithrombin III - Plasminogen activator inhibitor
 

  • References

  • 1 Mizock B. Septic shock. A metabolic perspective. Arch Intern Med 1984; 144: 579-585
    CrossrefPubMedGoogle Scholar
  • 2 Morrison DC, Ulevitch RJ. The effect of bacterial endotoxins on host mediation systems. A review. Am J Pathol 1978; 93: 526-617
    PubMedGoogle Scholar
  • 3 Bradley SG. Cellular and molecular mechanisms of action of bacterial endotoxins. Annu Rev Microbiol 1979; 33: 67-94
    CrossrefPubMedGoogle Scholar
  • 4 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
    CrossrefPubMedGoogle Scholar
  • 5 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 6 Colucci M, Paramo JA, Collen D. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
    CrossrefPubMedGoogle Scholar
  • 7 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedGoogle Scholar
  • 8 Juhan-Vague I, Moerman B, de Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
    CrossrefPubMedGoogle Scholar
  • 9 Páramo JA, Alfaro MJ, Rocha E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor. Relationship to deep vein thrombosis and influence of prophylaxis. Thromb Haemostas 1985; 54: 713-716
    PubMedGoogle Scholar
  • 10 Páramo JA, Colucci M, Collen D, Van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 1985; 291: 573-574
    CrossrefPubMedGoogle Scholar
  • 11 Páramo JA, De Boer A, Colucci M, Jonker JJ C, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis. Thromb Haemostas 1985; 54: 725
    PubMedGoogle Scholar
  • 12 Rocha E, Alfaro MJ, Páramo JA, Cañadell JM. Preoperative identification of patients at high risk of deep venous thrombosis despite prophylaxis in total hip replacement. Thromb Haemostas 1988; 59: 93-95
    PubMedGoogle Scholar
  • 13 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 14 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 15 Camacho Y, Navio G, Acosta J, Rocha E. Purification of pasteurized AT-III. Thromb Haemostas 1985; 54: 90 (Abstr).
    PubMedGoogle Scholar
  • 16 Merskey C, Lalezari P, Johnson AJ. A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proc Soc Exp Biol Med 1969; 131: 871-875
    CrossrefPubMedGoogle Scholar
  • 17 Loskutoff DJ, Mussoni L. Interactions between fibrin and the plasminogen activators produced by cultured endothelial cells. Blood 1983; 62: 62-68
    PubMedGoogle Scholar
  • 18 Bergstein JM, Michael AF. Renal cortical fibrinolytic activity in the rabbit following one or two doses of endotoxin. Thromb Diath Haemorrh 1973; 29: 27-32
    PubMedGoogle Scholar
  • 19 Colucci M, Páramo JA, Collen D. Inhibition of one-chain and two- chain forms of human tissue-type plasminogen activator by the fastacting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med 1986; 108: 53-59
    PubMedGoogle Scholar
  • 20 Schwartz BS, Monroe MC, Levin EG. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. Blood 1988; 71: 734-741
    PubMedGoogle Scholar
  • 21 Egbring R, Schmidt W, Fuchs G, Havermann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977; 49: 219-231
    PubMedGoogle Scholar
  • 22 Aasen AO, Ohlsson K. Release of granulocyte elastase in lethal canine endotoxin shock. Biol Chem Hoppe-Seyler 1978; 359: 683-690
    PubMedGoogle Scholar
  • 23 Colucci M, Páramo JA, Stassen JM, Collen D. Influence of the fastacting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue type plasminogen activator in rabbits. Interference of tissue-derived components. J Clin Invest 1986; 78: 138-144
    CrossrefPubMedGoogle Scholar
  • 24 Gelehrter TD, Scnycer-Laszuk R. Thrombin induction of plasminogen activator inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-169
    CrossrefPubMedGoogle Scholar
  • 25 Colucci M, Triggiani R, Cavallo LG, Semeraro N. Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor (PAI): evidence for a protein C (PC)-mediated mechanism. Fibrinolysis 1988; 2: 153 (Abstr).
    PubMedGoogle Scholar